A Bayesian approach to the survivor average causal effect in cluster-randomized crossover trials

summary

The gist

In cluster-randomized crossover (CRXO) trials, researchers often want to assess the effect of treatments on secondary non-terminal outcomes but frequently in these studies…

In short

This paper introduces a Bayesian method to estimate the survivor average causal effect (SACE) in cluster-randomized crossover trials, addressing data loss due to patient death. By augmenting posterior distributions with latent principal stratum membership, researchers can obtain robust estimates for this subgroup effect. Simulations show Model 1 performs well, and application to the PEPTIC trial yielded significant results regarding hospital stay differences.

Key concepts

Survivor Average Causal Effect (SACE)
This is a specific treatment effect calculated only among 'always-survivors'—patients who would survive regardless of which treatment they received. It represents the causal effect for this highly specific subgroup, allowing researchers to estimate outcomes where death prevents full measurement.
Principal Stratum Membership
This refers to classifying individuals into distinct groups based on their potential survival status under different treatments. The Bayesian approach uses latent variables to model this membership, helping the analysis account for the fact that not all patients can be fully observed due to mortality.
Bayesian Augmentation
The method improves standard Bayesian modeling by adding latent principal stratum membership information directly into the posterior distribution. This makes complex conditional posteriors more manageable for sampling algorithms like MCMC, allowing for more accurate estimation of the SACE.

Terminology used across episodes

This episode discusses

The paper

A Bayesian approach to the survivor average causal effect in cluster-randomized crossover trials · Read on arXiv

Dane Isenberg, Michael O. Harhay, Andrew B. Forbes, Paul J. Young, Fan Li, Nandita Mitra

Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania · Division of Quantitative Research Methodology, School of Public Health and Preventive Medicine, Monash University · Australian and New Zealand Intensive Care Research Centre Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University · Medical Research Institute of New Zealand Australian National Institute for Medical Research

Transcript

Introduction to the show: ident: Statistics. The day in statistics: methods, theory and the inference under them.

Tom: We're looking at the paper: "A Bayesian approach to the survivor average causal effect in cluster-randomized crossover trials".

Jane: Here's the gist of the paper. In cluster-randomized crossover (CRXO) trials, researchers often want to assess the effect of treatments on secondary non-terminal outcomes but frequently in these studies, there are patients who do not survive to have these measurements fully recorded <ref:2505.21447#pg2>.

Tom: This paper provides a causal inference framework and treatment effect estimation methods for addressing truncation by death in the setting of CRXO trials <ref:2505.21447#pg4>.

Jane: Target Estimand Definition The authors target the survivor average causal effect (SACE), a well-defined subgroup treatment effect obtained via principal stratification <ref:2505.21447#pg4>.

Tom: The SACE is defined as a causal contrast, often expressed in the literature as a difference in means, among the sub-population of “always-survivors” – individuals that would survive regardless of assigned treatment such that their non-mortality outcomes under either treatment are potentially observable <ref:2505.21447#pg4>.

Title and authors: Tom: So this paper is called "A Bayesian approach to the survivor average causal effect in cluster-randomized crossover trials," written by Isenberg, Harhay, Forbes, Young, Li, Mitra.

Jane: That title tells us right away that they're looking at how to measure an effect in a specific type of trial called a cluster-randomized crossover trial.

Lu: The authors are from a bunch of different places including the University of Pennsylvania and Monash University; that suggests they bring together different statistical traditions.

Meng: It sounds like they're trying to solve a problem where you have this complex randomization scheme, the CRXO design, but you want to know something specific about treatment effects that are hard to get out cleanly.

Lalam: They're focusing on something called the survivor average causal effect, or SACE; it’s a specific way they define an effect among people who survive regardless of what treatment they got.

Tom: Exactly, so it’s not about the average person in the trial, but this carefully selected subgroup—the always-survivors—and figuring out how the treatment affects them.

Jane: It's a refinement because when you look at standard trials, like individual-randomized trials, you need smaller sample sizes to get precise estimates than what we can achieve with this CRXO design.

The paper's summary: Tom: This paper explains that to tackle the problem of people dying before we measure their outcome, they are using a Bayesian approach where they add latent membership information about which group an individual belongs to.

Jane: They augment the posterior distribution with this principal stratum membership so that the conditional posteriors become easier to handle when they use Markov chain Monte Carlo sampling.

Lu: The core idea is that you can define this SACE as a causal contrast, which means it’s expressed as a difference in means or a ratio of means among those always-survivors.

Meng: They are using the concept of principal stratification to isolate this subgroup, which is the only group where you don't have to worry about whether their death status blocks your measurement of the outcome.

Lalam: Essentially, they use data augmentation with Polya-Gamma random variables to represent how much each individual contributes to each principal stratum they belong to.

Tom: They then run a simulation study on a two-period CRXO design and find that Model one which includes cluster random effects in the principal strata modeling and both cluster and cluster period random effects in the outcome modeling, shows low bias <ref:2505.21447#pg1>.

Jane: The implication here is that they show you how to estimate this SACE robustly even when dealing with truncation by death, which is a big hurdle in these types of clinical trials.

The paper's improvements: Tom: They suggest several improvements to their method, including evaluating performance across different model specifications like Model two or Model three <ref:2505.21447#pg1>.

Jane: One key improvement they highlight is that while it’s important to model the full hierarchy of random effects in the outcome modeling, you can simplify the principal strata modeling to keep estimation stable in small samples.

Lu: They found that dropping cluster-period random effects in the principal strata modeling doesn't hurt coverage of these SACE estimators as much as dropping them in the outcome modeling does.

Meng: From a deployment standpoint, it’s good news if you can simplify the model structure without losing statistical power or coverage for something critical like this effect.

Lalam: They also mention that they need to assume survival monotonicity, which is a structural assumption—that being assigned the active treatment doesn't make survival worse compared to the control treatment.

Tom: That assumption, survival monotonicity, is untestable and could be challenged in comparative effectiveness studies, which is a real limitation they flag.

Conclusion: Jane: So to wrap up, this paper proposes a Bayesian framework with data augmentation to estimate the SACE in cluster-randomized crossover trials by defining it as a causal contrast among always-survivors.

Tom: They showed that using Model one—the one with both cluster random effects in both modeling components—works really well in simulation, showing low bias and near nominal coverage for the SACE estimands across different scenarios <ref:2505.21447#pg1>.

Lu: The key contribution is showing how to use this method to estimate the survivor average causal effect in a setting where you have truncation by death, which is a big problem when looking at non-terminal outcomes.

Meng: For those of us shipping models, the practical point is that they have a framework that can handle this complexity without needing an impossibly complex model structure to run on real data.

Lalam: And for the PEPTIC trial they applied this, getting estimates for the difference in means in log days of zero point sixty-eight and a ratio of means in days of one point sixty-three among always-survivors.

Jane: Those numbers suggest a statistically significant increase in hospital stay for patients who got proton pump inhibitors compared to histamine two receptor blockers among the always-survivors.

Tom: That means the expected one day length among those on H2RBs is increased by about zero point sixty-three days, or one point five twelve hours for those on PPIs.

Lu: They also showed that Model one performs best overall compared to simpler models in terms of bias and root mean square error across the simulations they ran with one thousand simulated data sets <ref:2505.21447#pg1>.

Meng: It sounds like a solid way to go if you're trying to estimate these effects in real clinical settings where you can't afford massive computational overhead.

Lalam: In short, the paper "A Bayesian approach to the survivor average causal effect in cluster-randomized crossover trials" gives us a way to estimate this specific effect using a robust Bayesian framework.

More episodes

← Home